Generated by AI
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed to reduce the risk of platinum-induced hearing loss in pediatric patients receiving cisplatin-based chemotherapy. The company operates in the biotechnology and oncology supportive-care markets, serving hospitals, pediatric oncology specialists, and healthcare providers involved in cancer treatment. Based in Research Triangle Park, North Carolina, Fennec Pharmaceuticals is positioned as a commercial-stage company centered on a targeted therapy that supports quality of care for children undergoing chemotherapy.
Website68 TW Alexander Drive
Research Triangle Park, NC, 27709
United States
The latest articles about FENC.
Summary of May 14's posts. Generated by AI.
Summary of Sep 21's posts. Generated by AI.
Summary of Sep 21's posts. Generated by AI.
Investors talking about FENC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.